Unichem Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 23, 2025, 10:11 am

Quick Insight

Unichem Laboratories Ltd, trading at a price of 484 with a market capitalization of 3,418 Cr., has a P/E ratio of 27.4 and ROE and ROCE of 5.59% and 6.24% respectively. With an OPM of 14% and Net Profit of 138 Cr., the company's financial health seems stable. The ownership structure indicates strong promoter holding at 70.22%, while institutional investors hold a smaller stake with FIIs at 1.05% and DIIs at 11.63%. The company's healthy ICR of 14.27x and P/BV of 1.99x suggest a good financial position. However, the relatively low ROE and ROCE may indicate potential areas for improvement in operational efficiency to enhance shareholder value.

Competitors of Unichem Laboratories Ltd

All Competitor Stocks of Unichem Laboratories Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:50 am

Below is a detailed analysis of the quarterly data for Unichem Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 527.00 Cr.. The value appears to be declining and may need further review. It has decreased from 587.00 Cr. (Mar 2025) to 527.00 Cr., marking a decrease of 60.00 Cr..
• For Expenses, as of Jun 2025, the value is 504.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 503.00 Cr. (Mar 2025) to 504.00 Cr., marking an increase of 1.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 84.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 62.00 Cr..
• For OPM %, as of Jun 2025, the value is 4.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Mar 2025) to 4.00%, marking a decrease of 10.00%.
• For Other Income, as of Jun 2025, the value is 7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 2.00 Cr..
• For Interest, as of Jun 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 2.00 Cr..
• For Depreciation, as of Jun 2025, the value is 32.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 30.00 Cr. (Mar 2025) to 32.00 Cr., marking an increase of 2.00 Cr..
• For Profit before tax, as of Jun 2025, the value is -9.00 Cr.. The value appears to be declining and may need further review. It has decreased from 58.00 Cr. (Mar 2025) to -9.00 Cr., marking a decrease of 67.00 Cr..
• For Tax %, as of Jun 2025, the value is 16.00%. The value appears to be increasing, which may not be favorable. It has increased from 8.00% (Mar 2025) to 16.00%, marking an increase of 8.00%.
• For Net Profit, as of Jun 2025, the value is -10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 53.00 Cr. (Mar 2025) to -10.00 Cr., marking a decrease of 63.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is -1.49. The value appears to be declining and may need further review. It has decreased from 7.52 (Mar 2025) to -1.49, marking a decrease of 9.01.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 2:48 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 2:09 pm

Below is a detailed analysis of the balance sheet data for Unichem Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.00 Cr..
• For Reserves, as of Mar 2025, the value is 2,437.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,424.00 Cr. (Mar 2024) to 2,437.00 Cr., marking an increase of 13.00 Cr..
• For Borrowings, as of Mar 2025, the value is 460.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 248.00 Cr. (Mar 2024) to 460.00 Cr., marking an increase of 212.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 659.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 589.00 Cr. (Mar 2024) to 659.00 Cr., marking an increase of 70.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 3,569.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,275.00 Cr. (Mar 2024) to 3,569.00 Cr., marking an increase of 294.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,300.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,252.00 Cr. (Mar 2024) to 1,300.00 Cr., marking an increase of 48.00 Cr..
• For CWIP, as of Mar 2025, the value is 31.00 Cr.. The value appears to be declining and may need further review. It has decreased from 123.00 Cr. (Mar 2024) to 31.00 Cr., marking a decrease of 92.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
• For Other Assets, as of Mar 2025, the value is 2,239.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,898.00 Cr. (Mar 2024) to 2,239.00 Cr., marking an increase of 341.00 Cr..
• For Total Assets, as of Mar 2025, the value is 3,569.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,275.00 Cr. (Mar 2024) to 3,569.00 Cr., marking an increase of 294.00 Cr..

Notably, the Reserves (2,437.00 Cr.) exceed the Borrowings (460.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Unichem Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
• For Diluted EPS (Rs.), as of Mar 25, the value is 19.47. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.47, marking an increase of 29.48.
• For Cash EPS (Rs.), as of Mar 25, the value is 37.23. This value is within the healthy range. It has increased from 6.07 (Mar 24) to 37.23, marking an increase of 31.16.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 348.10. It has increased from 335.54 (Mar 24) to 348.10, marking an increase of 12.56.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 348.10. It has increased from 335.54 (Mar 24) to 348.10, marking an increase of 12.56.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 299.85. It has increased from 242.15 (Mar 24) to 299.85, marking an increase of 57.70.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 42.64. This value is within the healthy range. It has increased from 18.73 (Mar 24) to 42.64, marking an increase of 23.91.
• For PBIT / Share (Rs.), as of Mar 25, the value is 24.95. This value is within the healthy range. It has increased from 2.64 (Mar 24) to 24.95, marking an increase of 22.31.
• For PBT / Share (Rs.), as of Mar 25, the value is 21.96. This value is within the healthy range. It has increased from -8.76 (Mar 24) to 21.96, marking an increase of 30.72.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
• For PBDIT Margin (%), as of Mar 25, the value is 14.22. This value is within the healthy range. It has increased from 7.73 (Mar 24) to 14.22, marking an increase of 6.49.
• For PBIT Margin (%), as of Mar 25, the value is 8.31. This value is below the healthy minimum of 10. It has increased from 1.09 (Mar 24) to 8.31, marking an increase of 7.22.
• For PBT Margin (%), as of Mar 25, the value is 7.32. This value is below the healthy minimum of 10. It has increased from -3.61 (Mar 24) to 7.32, marking an increase of 10.93.
• For Net Profit Margin (%), as of Mar 25, the value is 6.51. This value is within the healthy range. It has increased from -4.13 (Mar 24) to 6.51, marking an increase of 10.64.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.51. This value is below the healthy minimum of 8. It has increased from -4.13 (Mar 24) to 6.51, marking an increase of 10.64.
• For Return on Networth / Equity (%), as of Mar 25, the value is 5.61. This value is below the healthy minimum of 15. It has increased from -2.98 (Mar 24) to 5.61, marking an increase of 8.59.
• For Return on Capital Employeed (%), as of Mar 25, the value is 6.81. This value is below the healthy minimum of 10. It has increased from 0.75 (Mar 24) to 6.81, marking an increase of 6.06.
• For Return On Assets (%), as of Mar 25, the value is 3.85. This value is below the healthy minimum of 5. It has increased from -2.22 (Mar 24) to 3.85, marking an increase of 6.07.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.17, marking an increase of 0.08.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.62. It has increased from 0.53 (Mar 24) to 0.62, marking an increase of 0.09.
• For Current Ratio (X), as of Mar 25, the value is 2.05. This value is within the healthy range. It has decreased from 2.40 (Mar 24) to 2.05, marking a decrease of 0.35.
• For Quick Ratio (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 1.40 (Mar 24) to 1.06, marking a decrease of 0.34.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.05. This value is below the healthy minimum of 4. It has decreased from 1.12 (Mar 24) to 1.05, marking a decrease of 0.07.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 14.27. This value is within the healthy range. It has increased from 5.82 (Mar 24) to 14.27, marking an increase of 8.45.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.54. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 7.54, marking an increase of 7.11.
• For Enterprise Value (Cr.), as of Mar 25, the value is 5,189.65. It has increased from 3,504.16 (Mar 24) to 5,189.65, marking an increase of 1,685.49.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.46. This value is within the healthy range. It has increased from 2.06 (Mar 24) to 2.46, marking an increase of 0.40.
• For EV / EBITDA (X), as of Mar 25, the value is 17.29. This value exceeds the healthy maximum of 15. It has decreased from 26.58 (Mar 24) to 17.29, marking a decrease of 9.29.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.31. This value is within the healthy range. It has increased from 2.02 (Mar 24) to 2.31, marking an increase of 0.29.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Price / BV (X), as of Mar 25, the value is 1.99. This value is within the healthy range. It has increased from 1.46 (Mar 24) to 1.99, marking an increase of 0.53.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.31. This value is within the healthy range. It has increased from 2.02 (Mar 24) to 2.31, marking an increase of 0.29.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.02 (Mar 24) to 0.02, marking an increase of 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness